The National Institute of Allergy and Infectious Diseases (NIAID) is seeking information from pharmaceutical and biopharmaceutical product developers on multivalent vaccines and rapidly adaptable vaccine platform technologies against filoviruses such as Ebola and Marburg.
The primary focus of this RFI is to gather information about multivalent filovirus vaccine candidates that at a minimum have shown efficacy in nonhuman primate disease models for at least one of the filovirus components.
NIAID is emphasizing interest in any multivalent filovirus vaccine candidates that incorporates technological enhancements, such as the following:
- Vaccine presentations or formulations that are stable without the need for cold chain
- Rapid onset of protective immunity that will permit a prophylaxis indication in a post-event scenario
- Minimal doses to achieve protection
- Reasonable complexity of vaccine components
- Non-parenteral routes of delivery
- Needle-free delivery
- Addressing issues such as anti-vector immunity and vaccine interference
- Maturity of immune assays that may be used to identify correlates of protection
Multivalent filovirus vaccine candidates that also incorporate a component to confer protection against Lassa Fever are of also noted to be of interest.
Further details are available via Solicitation Number: NOT-AI-15-049. The response deadline is September 4, 2015.
